<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780412</url>
  </required_header>
  <id_info>
    <org_study_id>Misoprostol</org_study_id>
    <nct_id>NCT04780412</nct_id>
  </id_info>
  <brief_title>Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section</brief_title>
  <official_title>Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal respiratory morbidities represent a common group of post natal complications&#xD;
      including respiratory distress syndrome, transient tachypnea of newborn, and persistent&#xD;
      pulmonary hypertension of newborn.&#xD;
&#xD;
      It is thought that preoperative vaginal misoprostol administration may decrease the incidence&#xD;
      of neonatal respiratory morbidity especially transient tachypnea of newborn. And therefore,&#xD;
      it may decrease the incidence of admission to neonatal intensive care units for respiratory&#xD;
      causes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of neonatal respiratory morbidity (NRM)</measure>
    <time_frame>up to 24 hours after birth</time_frame>
    <description>The incidence of neonatal respiratory morbidity, especially transient tachypnea of newborn, in early term neonates born to elective caesarian section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit (NICU) admission</measure>
    <time_frame>up to 24 hours after birth</time_frame>
    <description>The incidence of the need for neonatal intensive care unit admission during the first ten days after delivery in early term neonates born to elective caesarian section.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Transient Tachypnea of the Newborn</condition>
  <condition>Neonatal Respiratory Distress</condition>
  <arm_group>
    <arm_group_label>Misoprostol Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.</description>
    <arm_group_label>Misoprostol Group</arm_group_label>
    <other_name>prostaglandin E1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaginal placebo pills given 90-120 minutes before an elective caesarian section.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years or more.&#xD;
&#xD;
          -  Early term singleton pregnancy.&#xD;
&#xD;
          -  Elective caesarian section at (37 - 38+6) weeks of gestation.&#xD;
&#xD;
          -  Any indication for lower uterine segment caesarian section other than labor (as&#xD;
             malpresentations, severe preeclampsia, placenta previa with no previous bleeding&#xD;
             attacks, Diabetes Mellitus, macrosomic fetus, non reassuring cardiotocogram (CTG), and&#xD;
             fetal growth restriction).&#xD;
&#xD;
          -  Informed written consent signed by the participating pregnant woman.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women having any contraindication to Prostaglandin E1 as hypersensitivity, respiratory&#xD;
             disease (especially bronchial asthma), or glaucoma.&#xD;
&#xD;
          -  Any mental problems that block understanding of the nature and all the possible&#xD;
             consequences of the procedure and the study.&#xD;
&#xD;
          -  Pregnancies of known fetal diseases or chromosomal abnormalities.&#xD;
&#xD;
          -  Non-singleton pregnancies.&#xD;
&#xD;
          -  Emergency caesarian section as in ruptured membrane and women in labor pain.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samar A. Kandeel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University - Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University - Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Samar Ali</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachypnea</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Transient Tachypnea of the Newborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

